The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired a recorded discussion that also featured Nina Shah, Paul Richardson, Morie Gertz, and Heinz Ludwig. The topic of this discussion was “Integrating B-cell maturation antigen (BCMA)-directed agents in the treatment landscape for relapsed/refractory multiple myeloma”, which was identified as an unmet need within multiple myeloma treatment.
Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM
Mateos begins the discussion by posing the question of how to integrate chimeric antigen receptor (CAR) T-cell and other BCMA-directed products into clinical practice. Shah discusses the problems of CAR T-cell product availability, as well as the potential of bispecific therapies as they are more readily available. Richardson talks about antibody—drug conjugates (ADCs) and combination therapies, and the risk of keratopathy with some treatments. The committee discuss the convenience of ADCs and the potential of combinations using bispecific therapies and ADCs, with Gertz mentioning the exclusion of some patient subgroups from CAR T-cell trials, meaning bispecifics may be the best alternative for these individuals. Finally, Ludwig talks about the importance of more data becoming available to evaluate the use of BCMA-directed agents in earlier lines of therapy.
Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM